Search

ATLANTA: Alimera Sciences, Inc. has issued the following news release: Alimera Sciences, Inc. (Nasdaq: ALIM) ('Alimera'), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and [...]

Net Revenue up 54% to $27 Million vs. Q2 2023 Global End User Demand up 6% vs. Q2 2023 Company Recently Announced Definitive Merger Agreement with ANI Pharmaceuticals, Inc. ATLANTA, [...]

Net Revenue up 70% to $23 Million vs. Q1 2023 Global End User Demand Up 23% vs. Q1 2023 Reiterates Improved 2024 Net Revenue and Adjusted EBITDA Guidance ATLANTA, May [...]

Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE [...]

ATLANTA: Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced [...]

Net Revenue up 72% to $23.4 Million vs. Q3 2022 Net Loss Decreased by 74% to $1.4 Million vs. Q3 2022 Adjusted EBITDA of $5.4 Million in Q3 2023 Successful [...]

Alimera Acquired U.S. Commercial Rights to YUTIQ [sup. (R) ] Landmark NEW DAY Study Completed Enrollment with over 300 Patients Consolidated Net Revenue of $17.5 Million Up 20% vs. Second [...]

ATLANTA: Alimera Sciences, Inc., a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, announced financial [...]

-Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration remains on track to report topline data in December 2023 - -Phase 2 PAVIA clinical trial evaluating [...]

WATERTOWN: EyePoint Pharmaceuticals, Inc. has issued the following news release: EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with [...]

- Completed enrollment in the oversubscribed Phase 2 DAVIO 2 clinical trial evaluating EYP-1901 in wet age-related macular degeneration (AMD); topline data anticipated in 4Q 2023 - Enrollment ahead of [...]

WATERTOWN, Mass: EyePoint Pharmaceuticals, Inc. has issued the following news release: EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients [...]

- Phase 2 DAVIO 2 clinical trial in wet AMD on track with topline data anticipated by year-end 2023 - - Phase 2 PAVIA clinical trial in non-proliferative diabetic retinopathy [...]

- Initiated Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration (wet AMD) and Phase 2 PAVIA clinical trial for non-proliferative diabetic retinopathy (NPDR) - - Presented positive [...]

WATERTOWN, Mass., Aug 03, 2022 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NasdaqGM:EYPT), EQNX::TICKER_END - First patient dosed in the Phase 2 DAVIO 2 clinical trial for wet age-related macular degeneration [...]

WATERTOWN, Mass., Nov 03, 2021 (GLOBE NEWSWIRE via COMTEX) -- - Positive 3-month safety data for Phase 1 EYP-1901 DAVIO trial for the potential treatment of wet AMD featured at [...]

WATERTOWN, Mass.,: EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced financial results for the [...]

WATERTOWN, Mass., Aug 04, 2021 (GLOBE NEWSWIRE via COMTEX) -- Positive 30-Day Safety Data Reported for EYP-1901 DAVIO study for the potential treatment of wet AMD; study remains on track [...]

WATERTOWN, May 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- EQNX::TICKER_START (NasdaqGM:EYPT), EQNX::TICKER_END - EYP-1901 DAVIO study for the potential treatment of wet AMD dosed first patient in January; study remains [...]

WATERTOWN: EyePoint Pharmaceuticals, Inc. has issued the following news release: EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of [...]

WATERTOWN, Mar 04, 2021 (GLOBE NEWSWIRE via COMTEX) -- - $115.1 million follow-on financing completed in February 2021 - First patient dosed in Phase 1 clinical trial with EYP-1901 in [...]

WATERTOWN, Mass., Nov 05, 2020 (GLOBE NEWSWIRE via COMTEX) -- - Total revenues of $15.7 million and net product revenues of $5.8 million - - Sequential quarterly increase in underlying [...]

WATERTOWN, Mass., Oct 07, 2020 (GLOBE NEWSWIRE via COMTEX) -- - Q3 2020 net product revenues are estimated to be between $5.5 - $5.9 million, as healthcare facilities began reopening [...]

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported financial results for the first quarter ended March 31, 2020 and highlighted [...]

WATERTOWN, May 06, 2020 (GLOBE NEWSWIRE via COMTEX) -- - Total revenues of $7.5 million and net product revenues of $4.7 million - - Cash conservation and reorganization initiatives coupled [...]

WATERTOWN: EyePoint Pharmaceuticals, Inc. has issued the following press release: EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported financial results [...]

WATERTOWN, Mar 05, 2020 (GLOBE NEWSWIRE via COMTEX) -- - Total revenues of $8.6 million in Q4 2019 and $20.4 million for full year 2019 - - Net product revenues [...]

WATERTOWN, Mass., Jan 23, 2020 (GLOBE NEWSWIRE via COMTEX) -- - Q4 2019 total revenues are estimated to be between $7.5 - $8.2 million and full-year 2019 total revenues are [...]

Massachusetts: EyePoint Pharmaceuticals, Inc. has issued the following press release: EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported financial [...]

WATERTOWN, Mass., Nov 07, 2019 (GLOBE NEWSWIRE via COMTEX) -- - U.S. commercial launch trajectory for DEXYCU(R) and YUTIQ(R) gains momentum with strong customer order growth over Q2 - - [...]

WATERTOWN: EyePoint Pharmaceuticals, Inc. has issued the following press release: EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today reported financial [...]

WATERTOWN, Mass., Aug 07, 2019 (GLOBE NEWSWIRE via COMTEX) -- - Company reports total revenue of $7.2 million - - Two commercial product launches in U.S. are underway for DEXYCU [...]